MediWound Ltd. Earnings Recaps
Q3 2025
Nov 20, 2025
MediWound delivered a robust performance in Q3 2025, advancing clinical trials for EscharEx and expanding NexoBrid manufacturing, while bolstering its financial foundation with strategic financing.
Key takeaways
- Enrollment in the VALUE Phase III trial for EscharEx is progressing well, with 40 sites activated in the U.S. and Europe, although adjustments may affect timelines.
- NexoBrid's manufacturing capacity has expanded sixfold, positioning the company for future growth amidst rising global demand.
- Recent equity financing of $30 million enhances MediWound's financial flexibility to pursue growth strategies.
- NexoBrid achieved record quarterly revenues, with a 38% year-over-year increase reported by partner Vericel, indicating strong market penetration.
- Updates from Medicare on reimbursement rates may create competitive advantages for EscharEx in the complex wound care market.
Q2 2025
Aug 14, 2025
MediWound reported a strong second quarter with a 43% sequential revenue growth, propelled by NexoBrid's increasing market adoption and significant progress on the EscharEx VALUE Phase III trial.
Key takeaways
- Revenue reached $5.7 million, marking a 43% increase from Q1 2025 and a year-over-year rise from $5.1 million.
- NexoBrid achieved 52% year-over-year revenue growth in the U.S., indicating expanding market penetration and customer base.
- Gross profit improved to $1.3 million, reflecting a healthier revenue mix and operational efficiencies.
- Increased R&D investments of $3.5 million focus on advancing the EscharEx Phase III study.
- The company is on track for key manufacturing scale-up milestones by year-end, supported by substantial non-dilutive funding of $18.2 million from the U.S. Department of Defense.